BIMobject Reports Q4 Net Sales of MSEK 43.3, Up 7% Year-over-Year, EBITDA of MSEK -3.8

Augere Medical has strengthened its management team with Jon H. Hoem as CEO, Pia H. Smedsrud as Chief Medical Officer, and Ali Nobakht as Chief Strategy Officer. The company has also appointed Even Guttormsen as Chair of the Board. The new structure will focus on the European launch of the PolypAID system, expansion to other geographies, and technology development for improved polyp detection and new features.

Augere Medical, a Norwegian medical technology company specializing in artificial intelligence (AI) systems for improved polyp detection during colorectal cancer screenings, has announced significant changes to its management team and board of directors [1]. With recent MDR CE-mark approval and a successful NOK 23M financing round, Augere is poised for growth, focusing on the European launch of its PolypAID™ system, expansion to other geographies, and continued technology development.

New leadership appointments include Jon H. Hoem as CEO, Pia H. Smedsrud as Chief Medical Officer (CMO), Ali Nobakht as Chief Strategy Officer (CSO), and Even Guttormsen as Chair of the Board. Hoem, who previously served as Executive Chair, is thrilled to take on the daily management responsibilities, expressing gratitude to the board and former CEO David for his contributions during the transition period.

Smedsrud brings extensive experience as a CMO in the medical device industry, making her an ideal fit for Augere. Nobakht, a seasoned executive with a strong background in strategy and business development, will drive the company's growth initiatives. Guttormsen, a highly respected industry leader, will provide valuable guidance and support as the Chair of the Board.

The new management structure will enable Augere to allocate resources effectively, prioritizing the European launch of the PolypAID™ system, expanding to other geographies, and continuing technology development for enhanced polyp detection and new features. Augere's PolypAID™ system, currently available in Europe, is not yet accessible in other regions but is expected to be rolled out in the future.

With the recent appointments and ongoing growth, Augere Medical is confident in its ability to deliver innovative solutions for better colorectal cancer screening outcomes. For more information, please visit [www.augere.md](http://www.augere.md).

References:
[1] Augere Medical. (2025, February 14). Augere Medical strengthens its management team. Retrieved from https://www.globenewswire.com/news-release/2025/02/14/3026440/0/en/Augere-Medical-strengthens-its-management-team.html